NMIC Phthisiopulmonology and Infectious Diseases: Hepatitis Treatment Technology

2021: Developing Technology for Chronic Hepatitis B

July 21, 2021 it became known about the creation Russia in a unique technology for the treatment of chronic. About hepatitis B their achievement told in. National Medical Research Center for Phthisiopulmonology and Infectious Diseases Ministry of Health

For the first time in the world, a prototype of a pharmaceutical substance (active substance) was developed on the basis of site-directed nuclease proteins that can destroy over 99% of viral genomes in infected cells within a few days, RIA Novosti quoted the center as saying.

In Russia, learned to treat chronic hepatitis B

At the same time, scientists assured that this substance is completely non-toxic and safe to use. In the near future, a drug will be created on the basis of the developed active ingredient.

It is noted that by July 2021, more than 250 million patients with chronic hepatitis B. Every year, more than 1 million people die from this disease. At the same time, a complete cure for chronic hepatitis B is impossible. The Russian has developed gives hope for a correction of the situation.

Earlier, the head of Rospotrebnadzor Anna Popova reported that specialists at the Institute of Epidemiology developed a medical drug against chronic hepatitis B, which was planned to be released by 2022. Popova noted that the country has great success in preventing this disease. Over the past 15 years, the incidence of acute hepatitis B has decreased by 16 times. Here Russia is one of the leaders among other states, she said.

According to the head of the Reference Center for Viral Hepatitis of the Central Scientific Research Institute of Epidemiology of Rospotrebnadzor Vladimir Chulanov, diseases associated with chronic hepatitis B and C, in particular cancer and cirrhosis of the liver, claim more than 30 thousand lives a year. He noted that the most patients in the age group 35-50 years.^[1]

Notes